Neonatal Encephalopathy, MRI Lesions, and Later Epilepsy: No Harm, No Foul?

Risk Factors for Epilepsy in Children With Neonatal Encephalopathy.

We examined neonatal predictors of epilepsy in term newborns with neonatal encephalopathy (NE) by studying children enrolled in a longitudinal, single center cohort study. Clinical data were obtained through chart review, and MRI was performed in the neonatal period. We administered a seizure questionnaire to parents of children aged ≥12 mo (range, 12 mo to 16.5 y) to determine the outcome of epilepsy. The association between clinical predictors and time to onset of epilepsy was assessed using Cox proportional hazards regression. Thirteen of 129 children developed epilepsy: all had neonatal seizures and brain injury on neonatal MRI. Of the newborns with neonatal seizures, 25% (15.8/1000 person-years) developed epilepsy, with the highest hazard ratios (HRs) in the newborns with status epilepticus (HR, 35.8; 95% CI, 6.5–196.5). Children with severe or near-total brain injury were more likely to develop epilepsy compared with those with only mild or moderate injury (HR, 5.5; 95% CI, 1.8–16.8). In a multivariable analysis adjusting for degree of encephalopathy and severe/near-total brain injury, status epilepticus was independently associated with epilepsy. These data add to information regarding epilepsy pathogenesis and further aid clinicians to counsel parents regarding the likelihood that a newborn with NE will develop epilepsy.

Commentary
Neonatal encephalopathy refers to the clinical manifestations of acute perinatal brain injury, most commonly as a result of a hypoxic-ischemic insult. Neonatal seizures are a potentially treatable manifestation of moderate to severe neonatal encephalopathy and have long been recognized as a risk factor for later developmental deficits (1). The million-dollar question is: are seizures merely a marker for injury severity (2) or do neonatal seizures contribute to the injury (3)? If the latter is true, then seizures should be treated aggressively. However, neonatal seizures can only reliably be identified by electrographic monitoring (4) and are frequently refractory to anticonvulsant treatment (5). Further, there are theoretical reasons to be concerned that some treatment strategies for neonatal seizures could be toxic (6). Experimental anticonvulsant neurotoxicity has only been demonstrated with high dosages, has only been demonstrated acutely, and has only been demonstrated in normal animals rather than injured animals, let alone in animals with repetitive seizures. Nevertheless, the possibility of toxicity makes it all the more important to know whether successful treatment of neonatal seizures actually benefits the patient.

Unfortunately, the evidence regarding the harm conferred by neonatal seizures is complex, and the absence of effective therapies has made it impossible to rigorously test whether developmental outcomes are improved if seizures are stopped. Syndromes such as benign familial neonatal convulsions and transient hypocalcemia provide reasonable clinical evidence that neonatal seizures in otherwise healthy infants don’t cause obvious harm (7). Experimental data from otherwise healthy animals support the idea that perinatal seizures can be well tolerated (8), at least in modest amounts (3, 9). The key descriptor for both clinical and experimental studies is “otherwise healthy.” Recent experimental studies have found that seizures occurring in the setting of a variety of brain injuries do induce substantial neuronal death (10, 11). Further, experimental (12) and clinical (13) observations are leading to more effective treatments for neonatal seizures, and studies utilizing these new treatments are beginning to demonstrate improved neuronal survival after brain injury (14). However, direct evidence that the improved outcome is owing to improved seizure control has not yet been published.

The difficult clinical decisions as to how aggressively to search for and treat neonatal seizures can be made more confidently when we can accurately assess an encephalopathic neonate’s risk for permanent injury. One robust outcome is the development of chronic epilepsy. The National Collaborative Perinatal Project (NCPP) established that the risk of epilepsy after moderate to severe neonatal encephalopathy was 20 to 25 percent in survivors (15). The NCPP study collected neonatal
data from the dawn of intensive neonatal care: 1959 to 1965. Follow-up of these neonates did not include imaging, but an important finding was that in patients with early evidence of severe encephalopathy (10-minute Apgar score ≤3), the incidence of epilepsy was 0% in patients without cerebral palsy (i.e., motor manifestation of perinatal brain injury) versus 50% in patients who had motor manifestations of perinatal brain injury (15).

The NCPP data suggest that in the setting of neonatal encephalopathy, epilepsy after brain injury is far more likely when there are other manifestations of permanent brain injury. This finding is supported by a subsequent MRI study of survivors of neonatal encephalopathy that found epilepsy occurred only in patients with cerebral palsy. Further, epilepsy only occurred in patients with MRI evidence of perinatal injury (16). Similar findings were reported in a larger study by van Kooij et al. (17): all of the survivors of perinatal encephalopathy who developed epilepsy had moderate to severe MRI sequelae of perinatal injury; none of the survivors of neonatal encephalopathy with no or mild MRI changes developed epilepsy.

The report by Glass and coworkers now compellingly bridges the gap between 10-minute Apgar predictors, subsequent imaging data, and epilepsy. Glass and coworkers studied several risk factors including severity of neonatal encephalopathy, clinical and electrographically confirmed neonatal seizures, acute and convalescent MRI, and epilepsy. They found the same rate of epilepsy after neonatal seizures (25%) as the NCPP study from 50 years ago. Although etiologies of seizures have changed (e.g., hypocalcemic neonatal seizures are much less common now) and neonatal care has been revolutionized since the early 1960s, the care of neonatal seizures has not changed. Thus, the similar incidence of epilepsy, while not good news, may not be so surprising. Glass et al. also found that neonatal status epilepticus was associated with a much higher incidence of later epilepsy (83%). Excluding patients with status epilepticus, EEG-confirmed seizures conferred a much higher risk of subsequent epilepsy (26%) than clinical seizures (11%). This is congruent with the low correlation between clinical and electrographic signs of neonatal seizures (4). This finding supports the use of electrographic data as the gold standard for diagnosis of neonatal seizures. The high rate of false-positive clinical diagnoses of neonatal seizures may explain the poor predictive value of clinical neonatal seizures in some studies (2) as well as the efficacy of hypothermia for neonatal seizures diagnosed by electrographic (13) but not clinical (18) criteria. Thus, the data of Glass and coworkers confirmed the prior findings linking permanent injury and epilepsy and extended them to show that only patients with clear acute MRI evidence of neonatal injury developed epilepsy.

Bringing this back to the pressing question regarding care of newborns with neonatal encephalopathy: should we invest the considerable resources necessary to detect electrographic neonatal seizures (4)? The study by Glass and coworkers provides evidence for the utility of electrographic monitoring of cooled and at-risk neonates. The Glass study, along with all prior clinical outcome studies dating back to the NCPP report, also indicates that after neonatal brain insult, epilepsy only occurs in the setting of clinically and MRI-detectable permanent brain injury. Although this has sometimes been reduced in animal models to the catchy phrase “no hole, no epilepsy,” MRI sequelae of neonatal brain injury other than porencephaly are also predictive of later epilepsy. We still do not have a compelling answer for the companion question: how aggressively should we treat electrographic neonatal seizures? The answer to that question awaits more effective therapies. The good news is that new therapies are currently undergoing clinical trials (clinical.trials.gov NCT00830531, NCT01434225, NCT00884052, NCT01475656).

by Kevin Staley, MD

References

14. Liu Y, Shangguan Y, Barks JDE, Silversteinff FS. Bumetanide augments the neuroprotective efficacy of phenobarbital plus hypothermia in a


Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. **Identifying information.**
Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. **The work under consideration for publication.**
This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. **Relevant financial activities outside the submitted work.**
This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (DGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. **Other relationships**
Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
Section #1  Identifying Information

1.  Today’s Date: 10/3/2012
2.  First Name  Kevin    Last Name Staley  Degree MD
3.  Are you the Main Assigned Author?  ✔ Yes  □ No
   If no, enter your name as co-author:
4.  Manuscript/Article Title: Neonatal encephalopathy, MRI lesions, and later epilepsy: no harm no foul?
5.  Journal Issue you are submitting for:  12.4

Section #2  The Work Under Consideration for Publication
Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*  This means money that your institution received for your efforts on this study.
**  Use this section to provide any needed explanation.
Section #3  Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☑ No other relationships/conditions/circumstances that present a potential conflict of interest.
☐ Yes, the following relationships/conditions/circumstances are present:

Thank you for your assistance.
Epilepsy Currents Editorial Board